Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | UBE2N | P61088 | 1/20 | 0.67 |
| ▸ | HTR6 | P50406 | 12/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL946321 | 0.93 | KDM4E (0.57) | KDM4EUBE2NHTR6CYP3A4CYP2D6 | |
| SCHEMBL18080756 | 0.90 | KDM4E (0.67) | KDM4EUBE2NHTR6CYP3A4CYP2D6 | |
| SCHEMBL948577 | 0.88 | HTR6 (0.58) | KDM4EUBE2NHTR6CYP3A4CYP2D6 | |
| SCHEMBL947412 | 0.88 | KDM4E (0.58) | KDM4EUBE2NHTR6CYP3A4CYP2D6 | |
| SCHEMBL4776299 | 0.88 | HTR6 (0.62) | KDM4EUBE2NHTR6CYP3A4CYP2D6 | |
| SCHEMBL4778090 | 0.88 | KDM4E (0.52) | KDM4EUBE2NHTR6CYP3A4CYP2D6 | |
| SCHEMBL23589255 | 0.85 | HTR6 (0.55) | KDM4EUBE2NHTR6CYP3A4CYP2D6 | |
| SCHEMBL31571431 | 0.85 | HTR6 (0.55) | KDM4EUBE2NHTR6CYP3A4CYP2D6 | |
| SCHEMBL946840 | 0.84 | KDM4E (0.67) | KDM4EUBE2NHTR6L3MBTL1KLK7 | |
| SCHEMBL2134631 | 0.84 | KDM4E (0.67) | KDM4EUBE2NHTR6CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110845474-B | Target I-type PRMT compound and preparation method and application thereof | 四川大学 | 2021-01-12 | — | — | CN | disclosed |
| CN-110845474-A | Target I-type PRMT compound and preparation method and application thereof | 四川大学 | 2020-02-28 | — | — | CN | disclosed |
| US-7875605-B2 | 1-Benzenesulfonyl-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 H-indole; 1-[[5-Bromo-1-(2-Bromo-4-methoxybenzenesulfonyl)-indo1-3-yl]methyl][1,4]diazepane; useful for treating psychotic and neurodegenerative disorders e.g. schizophrenia, Alzheimer's disease, Parkinson's disease and Huntington's chorea | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-01-25 | — | — | US | disclosed |
| EP-1581492-B1 | N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | SUVEN LIFE SCIENCES LTD (IN) | 2008-07-16 | — | — | EP | disclosed |
| US-20060223890-A1 | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2006-10-05 | — | — | US | disclosed |
| EP-1581492-A1 | N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | Suven Life Sciences Limited (IN) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004048330-A1 | N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | SUVEN LIFE SCIENCES LIMITED (IN) | 2004-06-10 | — | — | WO | disclosed |
| US-6500849-B1 | ADMINISTERING ANTIINFLAMMATORY, ANTIPROLIFERATIVE, NOOTROPIC OR ANTIGROWTH AGENTS, SUCH AS 6-(1-DODECYNYL)-2-PYRIDINE-CARBOXALDEHYDE AND ENANTIOMORPHS TO MAMMALS; ALZHEIMERS DISEASE | AVENTIS PHARMACEUTICALS INC. | 2002-12-31 | — | — | US | disclosed |
| US-5977147-A | ANTITUMOR | HOECHST MARION ROUSSEL (US) | 1999-11-02 | — | — | US | disclosed |
| US-5614631-A | ANTIINFLAMMATORY AGENTS, ANTIGROWTH AGENTS, NOOTROPIC AGENTS, BACTERICIDES, FUNGICIDES | HOECHST MARION ROUSSEL, INC. (US) | 1997-03-25 | — | — | US | disclosed |
| US-5571923-A | 3-/1-DODECYL/-5-ISOXAZOLEMETHANOL INTERMEDIATE | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1996-11-05 | — | — | US | disclosed |
| US-5565584-A | CHEMICAL INTERMEDIATES | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1996-10-15 | — | — | US | disclosed |
| US-5557006-A | 1-Alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1996-09-17 | — | — | US | disclosed |
| US-5550247-A | ANTIINFLAMMATORY AGENT, ANTITUMOR AGENT, COGNITION ACTIVATORS, BACTERICIDES, FUNGICIDES | HOECHST ROUSSEL PHARMACEUTICALS INC. (US) | 1996-08-27 | — | — | US | disclosed |
| US-5534640-A | REDUCING INFLAMMATION AND CELL PROLIFERATION, COGNITION ACTIVATORS, BACTERIOSTATS, FUNGISTATS | HOECHST ROUSSEL PHARMACEUTICALS INC. (US) | 1996-07-09 | — | — | US | disclosed |
| US-5534636-A | ANTIINFLAMMATORY AGENTS, ANTITUMOR AGENT, COGNITION ACTIVATORS,BACTERICIDES, AND FUNGICIDES | HOECHST ROUSSEL PHARMACEUTICALS INC. (US) | 1996-07-09 | — | — | US | disclosed |
| US-5519062-A | ANTIINFLAMMATORY | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1996-05-21 | — | — | US | disclosed |
| US-5488063-A | ANTIINFLAMMATORY, ANTICARACINOGENIC AGENTS; BACTERICIDES, FUNGICIDES | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1996-01-30 | — | — | US | disclosed |
| US-5488061-A | ANTIINFLAMMATORY, ANTICARACINOGENIC AGENTS; BACTERICIDES, FUNGICIDES | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1996-01-30 | — | — | US | disclosed |
| US-5360811-A | 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223890-A1 | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them | HTR3A, HTR3C, HTR2C | KDM4E 3995/4885UBE2N 1597/4885HTR6 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.